Intellia Therapeutics (FRA:38I) General and Admin. Expense : €114.83 Mil (TTM As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Intellia Therapeutics General and Admin. Expense?

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Intellia Therapeutics's General and Admin. Expense for the three months ended in Mar. 2025 was €26.83 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2025 was €114.83 Mil.

Intellia Therapeutics General and Admin. Expense Historical Data

The historical data trend for Intellia Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intellia Therapeutics General and Admin. Expense Chart

Intellia Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

General and Admin. Expense

Get a 7-Day Free Trial

36.31

62.92

85.25

106.83

120.17

Intellia Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
General and Admin. Expense	Get a 7-Day Free Trial															28.60	29.54	27.48	30.98	26.83

Intellia Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €114.83 Mil.

Intellia Therapeutics General and Admin. Expense Related Terms

Thank you for viewing the detailed overview of Intellia Therapeutics's General and Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Intellia Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intellia Therapeutics Inc (FRA:38I) » Definitions » General and Admin. Expense

Comparable Companies

Traded in Other Exchanges

NTLA:USA 0JBU:UK 38I:Germany

Address

40 Erie Street, Suite 130, Cambridge, MA, USA, 02139

Website

https://www.intelliatx.com

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics Headlines

No Headlines